Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of OJP-001 plus 5-ALA in relapsed/recurrent adult T-cell leukemia/lymphoma with peripheral blood tumor
jRCT2071240003Phase 2Recruiting
- Sponsor
- JIMRO
- Start
- Apr 2024
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid + OJP-001 in adult T-cell leukemia-lymphoma (ATLL), sponsored by JIMRO. Primary endpoints: Dose limiting toxicity (Phase I) and Best overall response rate (Phase II). Started Apr 2024; status: recruiting.
02
Drugs
5-aminolevulinic acid + OJP-001
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2071240003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240003.